Ironwood Pharmaceuticals
IRWD
200 hedge funds and large institutions have $229M invested in Ironwood Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 74 increasing their positions, 63 reducing their positions, and 51 closing their positions.
164,720% more call options, than puts
Call options by funds: $16.5M | Put options by funds: $10K
17% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 63
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
5.46% less ownership
Funds ownership: 102.61% → 97.15% (-5.5%)
10% less funds holding
Funds holding: 223 → 200 (-23)
43% less first-time investments, than exits
New positions opened: 29 | Existing positions closed: 51
69% less capital invested
Capital invested by funds: $727M → $229M (-$499M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$10.1M |
| 2 |
Millennium Management
New York
|
+$9.95M |
| 3 |
Jane Street
New York
|
+$7.37M |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$7.26M |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
+$5.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$26.6M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$23.7M |
| 3 |
State Street
Boston,
Massachusetts
|
-$11.5M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.15M |
| 5 |
Morgan Stanley
New York
|
-$5.15M |
IRWD Hedge Fund Activity: Q1 2025 in Review
200 of the 7,472 institutional investors tracked by Wall St. Rank reported a position in Ironwood Pharmaceuticals (IRWD) for Q1 2025, worth a combined $229M — down 69% from $727M a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of IRWD and 29 opened new positions — a net loss of 22 holders — while 63 trimmed existing stakes and 74 added.
The largest buyer was Armistice Capital, adding an estimated $10.1M. The largest seller was BlackRock, cutting an estimated $26.6M.
- 200 institutional investors held Ironwood Pharmaceuticals (IRWD) as of Q1 2025, down from 223 in Q4 2024.
- Funds reported $229M of Ironwood Pharmaceuticals stock for Q1 2025, down 69% quarter-over-quarter.
- 29 funds opened new Ironwood Pharmaceuticals positions in Q1 2025 and 51 closed out, a net change of -22 holders.
- The largest Ironwood Pharmaceuticals buyer in Q1 2025 was Armistice Capital, an estimated $10.1M added.
- The largest Ironwood Pharmaceuticals seller in Q1 2025 was BlackRock, an estimated $26.6M sold.
Based on aggregated 13F filings for Q1 2025.